|
Mimetic
|
Cancer
|
Cell Type
|
Combined
|
Apoptosis
|
Ref
|
|---|
|
Gossypol
|
Glioblastoma
|
Diff13–20, TS13–20
|
temozolomide resistance
|
–
|
[180]
|
|
Gossypol
|
CML
|
K562
|
imatinib
|
–
|
[181]
|
|
Gossypol
|
Colon
|
HT-29 cells, HCT116, RKO
|
fluorouracil
|
–
|
[182]
|
|
Gossypol
|
Nasopharyngeal, Breast, Gastric
|
MCF-7, YC116, CNE2
|
gemcitabine
|
–
|
[183]
|
|
Gossypol
|
Ovarian
|
OVCAR-3 and MDAH-2774
|
zoledronic acid
|
–
|
[184]
|
|
Gossypol
|
Thoracic
|
H460, TE2, H211
|
TRAIL
|
–
|
[185]
|
|
AT-101
|
Bladder
|
UM-UC2, UM-UC9
|
gemcitabine, carboplatin
|
synergized
|
[167]
|
|
AT-101
|
Breast
|
SKBR-3, MDA-MB-453
|
trastuzumab
|
–
|
[186]
|
|
AT-101
|
Pancreatic
|
BxPC-3
|
genistein
|
–
|
[187]
|
|
AT-101
|
Prostate
|
PC-3 and xenograft
|
radiation
|
–
|
[188]
|
|
AT-101
|
Prostate
|
PC-3 xenograft
|
docetaxel
|
synergized
|
[170]
|
|
AT-101
|
Prostate
|
DU145, PC-3
|
sorafenib
|
–
|
[174]
|
|
AT-101
|
Prostate
|
VCaP
|
bicalutamide
|
–
|
[189]
|
- The therapeutic type is highlighted in bold (left column), non-synergy is highlighted by ‘-‘and the corresponding studies are referenced in the right column (Ref). Abbreviations: CML Chronic Myelogenous Leukemia
